|
SRP54 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.57979999995772E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.16319999999781E-05 |
| Normal-vs-Stage2 |
1.957240E-03 |
| Normal-vs-Stage3 |
6.84089999980486E-07 |
| Normal-vs-Stage4 |
2.5203999998169E-07 |
| Stage1-vs-Stage2 |
7.409200E-01 |
| Stage1-vs-Stage3 |
1.041570E-01 |
| Stage1-vs-Stage4 |
4.091600E-02 |
| Stage2-vs-Stage3 |
4.578800E-01 |
| Stage2-vs-Stage4 |
2.201800E-01 |
| Stage3-vs-Stage4 |
4.517800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.64839999994682E-07 |
| Normal-vs-AfricanAmerican |
4.541700E-02 |
| Normal-vs-Asian |
6.808800E-04 |
| Caucasian-vs-AfricanAmerican |
2.269400E-01 |
| Caucasian-vs-Asian |
6.243400E-01 |
| AfricanAmerican-vs-Asian |
4.860000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.74440000514309E-08 |
| Normal-vs-Female |
5.7436999999938E-05 |
| Male-vs-Female |
2.304500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.18719999999628E-05 |
| Normal-vs-Age(41-60Yrs) |
1.9725000000026E-06 |
| Normal-vs-Age(61-80Yrs) |
1.06779999997642E-06 |
| Normal-vs-Age(81-100Yrs) |
6.289800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.511400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.006220E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.343400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.604000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.422000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.689600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.419800E-01 |
| Classical-VS-Follicular |
1.775240E-01 |
| Classical-VS-Other |
9.093900E-02 |
| Classical-VS-Normal |
3.82290000000562E-05 |
| Tall-VS-Follicular |
9.802200E-01 |
| Tall-VS-Other |
2.813000E-01 |
| Tall-VS-Normal |
7.72910000000904E-05 |
| Follicular-VS-Other |
4.264200E-01 |
| Follicular-VS-Normal |
2.4578999999969E-05 |
| Other-VS-Normal |
1.057590E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.53500000002971E-07 |
| Normal-vs-N1 |
1.51894999999014E-05 |
| N0-vs-N1 |
2.996800E-01 |
|
|
